Materjalid

Materjalid

Uurige IMPACT Academy materjale, mille on heaks kiitnud meie ekspertkomisjon.

Palun sisestage vähemalt kolm tähemärki
Featured
VIIMATI LISATUD

Soovituslik

COVID-19 and its implications in heart failure
ESITLUS
COVID-19 and its implications in heart failure
Vaata sisu
Can new-onset diabetes be prevented
ESITLUS
Can new-onset diabetes be prevented
Vaata sisu
Practicalities of SGLT2 inhibition – pros vs cons
Infograafik
Practicalities of SGLT2 inhibition – pros vs cons
Vaata sisu
Updates on ESC heart failure guidelines
VIDEO
Updates on ESC heart failure guidelines
Vaata sisu
Cardiologist Practical Guide to Prescribing
Infograafik
Cardiologist Practical Guide to Prescribing
Vaata sisu
Cardiovascular
VIIMATI LISATUD

Südame-veresoonkonna haigused

Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
VIDEO
Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
Vaata sisu
What did the study tell us about the safety of medicines in heart failure?
Infograafik
What did the study tell us about the safety of medicines in heart failure?
Vaata sisu
Hiding in plain sight – how to detect heart failure in primary care
VIDEO
Hiding in plain sight – how to detect heart failure in primary care
Vaata sisu
Optimizing HF discharge care and follow-up
Infograafik
Optimizing HF discharge care and follow-up
Vaata sisu
Vaata kõiki Südame-veresoonkonna haigused ressursse
Infection and Vaccines
VIIMATI LISATUD

Infektsioonhaigused ja vaktsiinid

Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
VIDEO
Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
Vaata sisu
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
Infograafik
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
Vaata sisu
Clinical recommendations for the management of type 2 diabetes
VIDEO
Clinical recommendations for the management of type 2 diabetes
Vaata sisu
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Infograafik
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Vaata sisu
Vaata kõiki Infektsioonhaigused ja vaktsiinid ressursse
Metabolic
VIIMATI LISATUD

Diabeet

Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
VIDEO
Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
Vaata sisu
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
Infograafik
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
Vaata sisu
Clinical recommendations for the management of type 2 diabetes
VIDEO
Clinical recommendations for the management of type 2 diabetes
Vaata sisu
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
Infograafik
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
Vaata sisu
Vaata kõiki Diabeet ressursse
Oncology
VIIMATI LISATUD

Kasvajad

What did the study tell us about the safety of medicines in heart failure?
Infograafik
What did the study tell us about the safety of medicines in heart failure?
Vaata sisu
Hiding in plain sight – how to detect heart failure in primary care
VIDEO
Hiding in plain sight – how to detect heart failure in primary care
Vaata sisu
Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
VIDEO
Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
Vaata sisu
Clinical recommendations for the management of type 2 diabetes
VIDEO
Clinical recommendations for the management of type 2 diabetes
Vaata sisu
Vaata kõiki Kasvajad ressursse
Rare Disease
VIIMATI LISATUD

Harvikhaigused

Hiding in plain sight – how to detect heart failure in primary care
VIDEO
Hiding in plain sight – how to detect heart failure in primary care
Vaata sisu
Clinical recommendations for the management of type 2 diabetes
VIDEO
Clinical recommendations for the management of type 2 diabetes
Vaata sisu
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
Infograafik
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
Vaata sisu
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Infograafik
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Vaata sisu
Vaata kõiki Harvikhaigused ressursse
Renal
VIIMATI LISATUD

Neeruhaigused

Chronic kidney disease management
VIDEO
Chronic kidney disease management
Vaata sisu
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Infograafik
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Vaata sisu
Kidney outcomes associated with inhibition of SGLT2
VIDEO
Kidney outcomes associated with inhibition of SGLT2
Vaata sisu
Medicines in chronic kidney disease
Infograafik
Medicines in chronic kidney disease
Vaata sisu
Vaata kõiki Neeruhaigused ressursse
Respiratory and Immunology
VIIMATI LISATUD

Hingamisteed ja immunoloogia

What did the study tell us about the safety of medicines in heart failure?
Infograafik
What did the study tell us about the safety of medicines in heart failure?
Vaata sisu
Clinical recommendations for the management of type 2 diabetes
VIDEO
Clinical recommendations for the management of type 2 diabetes
Vaata sisu
Chronic kidney disease management
VIDEO
Chronic kidney disease management
Vaata sisu
Medicines in chronic kidney disease
Infograafik
Medicines in chronic kidney disease
Vaata sisu
Vaata kõiki Hingamisteed ja immunoloogia ressursse
Featured
VIIMATI LISATUD

Enim Loetud

The story of heart failure prevention with SGLT2 inhibitors in diabetes: Key learnings for cardiologist
ESITLUS
The story of heart failure prevention with SGLT2 inhibitors in diabetes: Key learnings for cardiologist
Vaata sisu
Cardiologist Practical Guide to Prescribing
Infograafik
Cardiologist Practical Guide to Prescribing
Vaata sisu
Safety and tolerability of SGLT2 inhibitors – how and when should I initiate treatment
VIDEO
Safety and tolerability of SGLT2 inhibitors – how and when should I initiate treatment
Vaata sisu
Cardiorenal benefits of SGLT2 inhibitors
ESITLUS
Cardiorenal benefits of SGLT2 inhibitors
Vaata sisu
Diagnosis and co-morbidities of chronic kidney disease
VIDEO
Diagnosis and co-morbidities of chronic kidney disease
Vaata sisu